Scientific program
The final program for the LION Conference 2024 is in the works. Further information will be published shortly. So, check back soon.
Preliminary program – Tuesday, November 12, 2024
9:15–9:45 am
Check-In
9:45–10:00 am
Welcome
10:00–11:30 am
Session I
Cellular therapy in lymphoma
Keynote Sureda, Anna (Catalan Institute of Oncology, Barcelona, Spain)
Efficacy of "universal" CAR-T cells in a humanised model of primary CD7+CD33+ acute myeloid leukemia
Kloos, Arnold
Targeted modulation of the NKG2D axis to trigger anti-leukemia and anti-lymphoma NK cell & T cell responses
Winterberg, Dorothee
Endothelial dysfunction and hyperinflammation is linked with severe hematotoxicity after CAR-T therapy
Scheller, Lukas
11:30–11:45 am
Break
11:45 am – 12:45 pm
Poster session I
CAR-NK cell therapies for treatment of severe autoimmune diseases
Arriens, Marieke
Synthesis and biological evaluation of histone deacetalyse inhibitors for more effective CAR-T cell therapy
Bauer, Leoni
A novel NK cell expansion method using a multifunctional fusion protein for the development of cell-based immunotherapies
Boje, Ammelie
Shifting gears in CAR T cell manufacturing: LNPs and AAVs as in vivo solutions
Cetin, Ela
Continously monitored NK-killing assays for kinetic evaluation of primary subpopulations
Chen, Po-Chun
Anti-CD123-CAR-NK-92 cells reduce monocyte population in human blood – a potential risk of infection susceptibility for the patient?
Dehmel, Susann
Scaling up mRNA-based CAR-T cell manufacturing using lipid nanoparticles
Gebhardt, Clara
CD123- and CD33-targeting primary CAR-NK cell preparations for treatment of acute myeloid leukemia
Gierschek, Fenja
Towards scalable allogeneic CAR-T manufacturing: Perfusion optimisation and multi-litre scale-up in single-use stirred-tank bioreactors
Hengst, Julia
Optimized scRNA-Seq omics workflow for high-resolution CAR T cell profiling
Kuhn, Christina
Ex vivo modification of hematopoietic cell transplants in GvHD prevention: Single treatment with the anti-human CD4 antibody MAX.16H5 can outperform state-of-the-art immunosuppressants
Roth, Kristina
Automated clinical-grade manufacturing of CAR-NK cells using BaEV-LV on CliniMACS Prodigy
Sarisoy, Cem
Accelerating innovation in chimeric antigen receptors: Harnessing mRNA for rapid screening
Serfling, Robert
Identification and classification of CAR vector insertion sites using long-read DNA sequencing
Weich, Adrian
12:45–1:30 pm
Break
1:30–2:15 pm
Janssen industry symposium "CAR-T cells"
Supported by Janssen-Cilag GmbH
Novel technologies for T cell directing targets
Abken, Hinrich (RCI – University of Regensburg, Regensburg, Germany)
Management of toxicities and patient selection of CAR-T cell therapies
Fricke, Stephan (Klinikum Chemnitz)
2:15–2:30 pm
Break
2:30–4:00 pm
Session II
NK cell research and transfer towards cancer immuno therapy
Keynote Mandelboim, Ofer (The Hebrew University of Jerusalem, Jerusalem, Israel)
Clinical experiences on NK cell based cancer immuno therapy
Keynote Alici, Evren (Karolinska Institutet, Stockholm, Sweden)
Off-the-shelf chimeric antigen receptor-modified natural killer cells to target cervical cancer and the tumor microenvironment
Polten, Robert
Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss
Eitler, Jiri
4:00–5:00 pm
Poster session II
Modulation of CD8 T cell responses at the human ex vivo tumor front
Bargmann, Tonia
Interleukin-2 induces type 2 and 17 skin inflammation in a CD25-dependent manner
Dehmel, Susann
Immune competent 3D pancreatic adenocarcinoma (PDAC) organoid-on-chip model for preclinical drug testing
Deipenbrock, Alina
Navigating phase-appropriate potency testing for cell and gene therapy products
Fiedorowicz, Alicja
Immune cells play a critical role in cytokine- and endotoxin-mediated endothelial permeability
Gogesch, Patricia
Looking for stable neo-antigens across different splice factor-mutated malignancies
Güse, Esther
LEDGF/p75 - a possible prognostic biomarker candidate for colorectal cancer?
Liedtke, Victoria
Ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy
Lischer, Christopher
Pd(II) coumarin complexes as potential agents against breast carcinoma
Pecić, Katarina
Development of a novel therapeutic approach for inflammatory bowel disease targeting IL-12/IL-23p40 through endogenously produced recombinant IL-12p80
Pethaperumal, Subha Shree
From solo to duet: Combining CAR-modified immune cells for efficient cancer immunotherapy
Silva Ferreira, Francisca
Quantitative profiling of MHC class I and class II antigens and neoantigens for discovery and targeted applications using an optimized mass spectrometry-based workflow
Stefanoska, Despina
Promoting long-term persistence and efficacy of CAR-T cells and adoptive cellular products by the restoration of their autophagy machinery
Theinert, Tobias
CAR T cell-mediated cytotoxicity and cytokine release in response to varying levels of antigen expression on target cells and production methods
Yu, Zhong
5:00–7:00 pm
Session III
Immune landscape of liver cancer
Keynote Schirmacher, Peter (Heidelberg University Hospital, Heidelberg, Germany)
Immunotherapy for upper gastrointestinal cancers
Keynote Janjigian, Yelena (Memorial Sloan Kettering Cancer Center, New York, USA)
NTX1088: Pioneering the future of immuno-oncology through PVR blockade
Keynote Tsukerman, Pini (Nectin Therapeutics Ltd, Jerusalem, Israel)
CD109 as a target for lung cancer and tumor-associated macrophages
Haesen, Tine
NK cell engagers targeting NKp30 and epidermal growth factor receptor (EGFR) on solid tumor cells induce potent lysis and pro-inflammatory cytokine release
Klausz, Katja
7:00 pm
Get-together
Preliminary program – Wednesday, November 13, 2024
9:00–9:45 am
Gilead industry symposium "Explore the future role of CAR T in addressing unmet needs in 1L DLBCL"
Supported by Gilead Sciences GmbH
Discussion on how CAR T therapy management is evolving and highlighting innovations in design and manufacturing
9:45–10:00 am
Break
10:00–11:15 am
Session IV
Towards clinical implementation: AAV for cancer gene therapy
Keynote Büning, Hildegard (Medical University Hannover, Hannover, Germany)
Lessons learned from AAV-mediated optogenetic hearing restoration
Keynote Moser, Tobias (Georgn August University Göttingen, Göttingen, Germany)
Quality by Design for AAV process development
Schmid, Thomas
11:15–11:45 am
Break
11:45 am – 12:30 pm
Astra Zeneca industry symposium "Advancing immunotherapy in GI cancers and haematology"
Supported by AstraZeneca
The ABC of GI-oncology: ADCs, bispecifics & CAR-T
Lordick, Florian (University Medicine Leipzig, Leipzig, Germany)
Targeting CD19 beyond CAR-T
Topp, Max (University Hospital of Würzburg, Würzburg, Germany)
12:30 – 1:15 pm
Break
1:15 – 2:00 pm
Bristol Myers Squibb industry symposium "Long-term success of immunotherapy in tumor control in NSCLC and GI tumors"
Supported by Bristol-Myers Squibb GmbH & Co. KGaA
Long-term success with GI tumors - focus on IO combination therapies
Lordick, Florian (University Medicine Leipzig, Leipzig, Germany)
Double immunotherapy for NSCLC: Long-term success and practical insights
Wolf, Martin (Klinikum Kassel, Kassel, Germany)
2:00 – 2:15 pm
Break
2:15– 4:00 pm
Session V
CRISPR and base edited T cells
Keynote Qasim, Waseem (University College London, London, UK)
Nonviral gene and RNA delivery in the context of immunotherapies
Keynote Schiffelers, Raymond (University Medical Center Utrecht, Utrecht, The Netherlands)
Single-cell multiomic dissection of toxicity and response to BCMA-directed CAR T cells
Rade, Michael
Zebrafish as a novel in vivo model to assess CAR-NK cell efficacy against metastatic breast cancer
Murali Shankar, Nivedha
Innovative approaches to improve nonclinical safety assessment of CAR‑T cells and immunomodulatory biotherapeutics: The imSAVAR project
Alb, Miriam
Archive
Scientific program 2023 – Download [PDF]
Scientific program 2022 – Download [PDF]
Scientific program 2021 – Download [PDF]
